Literature DB >> 21807998

Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas.

Elisabetta Botti1, Giulia Spallone, Francesca Moretti, Barbara Marinari, Valentina Pinetti, Sergio Galanti, Paolo D'Onorio De Meo, Francesca De Nicola, Federica Ganci, Tiziana Castrignanò, Graziano Pesole, Sergio Chimenti, Luisa Guerrini, Maurizio Fanciulli, Giovanni Blandino, Michael Karin, Antonio Costanzo.   

Abstract

The transcription factor interferon regulatory factor 6 (IRF6) regulates craniofacial development and epidermal proliferation. We recently showed that IRF6 is a component of a regulatory feedback loop that controls the proliferative potential of epidermal cells. IRF6 is transcriptionally activated by p63 and induces its proteasome-mediated down-regulation, thereby limiting keratinocyte proliferative potential. We hypothesized that IRF6 may also be involved in skin carcinogenesis. Hence, we analyzed IRF6 expression in a large series of squamous cell carcinomas (SCCs) and found a strong down-regulation of IRF6 that correlated with tumor invasive and differentiation status. IRF6 down-regulation in SCC cell lines and primary tumors correlates with methylation on a CpG dinucleotide island located in its promoter region. To identify the molecular mechanisms regulating IRF6 potential tumor suppressive activity, we performed a genome-wide analysis by combining ChIP sequencing for IRF6 binding sites and gene expression profiling in primary human keratinocytes after siRNA-mediated IRF6 depletion. We observed dysregulation of cell cycle-related genes and genes involved in differentiation, cell adhesion, and cell-cell contact. Many of these genes were direct IRF6 targets. We also performed in vitro invasion assays showing that IRF6 down-regulation promotes invasive behavior and that reintroduction of IRF6 into SCC cells strongly inhibits cell growth. These results indicate a function for IRF6 in suppression of tumorigenesis in stratified epithelia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21807998      PMCID: PMC3158164          DOI: 10.1073/pnas.1110931108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase.

Authors:  Y Hu; V Baud; M Delhase; P Zhang; T Deerinck; M Ellisman; R Johnson; M Karin
Journal:  Science       Date:  1999-04-09       Impact factor: 47.728

Review 2.  Host response in tumor growth and progression.

Authors:  S Michelson; J T Leith
Journal:  Invasion Metastasis       Date:  1996

3.  A new in vitro assay for quantitating tumor cell invasion.

Authors:  L A Repesh
Journal:  Invasion Metastasis       Date:  1989

Review 4.  Genetic events and the role of TGF beta in epithelial tumour progression.

Authors:  R J Akhurst; A Balmain
Journal:  J Pathol       Date:  1999-01       Impact factor: 7.996

5.  ΔNp63α is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis.

Authors:  William M Keyes; Matteo Pecoraro; Victoria Aranda; Emma Vernersson-Lindahl; Wangzhi Li; Hannes Vogel; Xuecui Guo; Elvin L Garcia; Tatyana V Michurina; Grigori Enikolopov; Senthil K Muthuswamy; Alea A Mills
Journal:  Cell Stem Cell       Date:  2011-02-04       Impact factor: 24.633

Review 6.  The role of cell adhesion molecules and proteases in tumor invasion and metastasis.

Authors:  M J Bussemakers; J A Schalken
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 7.  Cancer epigenetics comes of age.

Authors:  P A Jones; P W Laird
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

Review 8.  The role of cell adhesion molecules in cancer invasion and metastasis.

Authors:  J Behrens
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes.

Authors:  Shinji Kondo; Brian C Schutte; Rebecca J Richardson; Bryan C Bjork; Alexandra S Knight; Yoriko Watanabe; Emma Howard; Renata L L Ferreira de Lima; Sandra Daack-Hirsch; Achim Sander; Donna M McDonald-McGinn; Elaine H Zackai; Edward J Lammer; Arthur S Aylsworth; Holly H Ardinger; Andrew C Lidral; Barbara R Pober; Lina Moreno; Mauricio Arcos-Burgos; Consuelo Valencia; Claude Houdayer; Michel Bahuau; Danilo Moretti-Ferreira; Antonio Richieri-Costa; Michael J Dixon; Jeffrey C Murray
Journal:  Nat Genet       Date:  2002-09-03       Impact factor: 38.330

View more
  64 in total

1.  Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.

Authors:  Alexi Surette; Byong Hoon Yoo; Tallal Younis; Kara Matheson; Tarek Rameh; Jaime Snowdon; Gillian Bethune; Kirill V Rosen
Journal:  Breast Cancer Res Treat       Date:  2021-03-16       Impact factor: 4.872

2.  Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.

Authors:  Thomas Fleischer; Arnoldo Frigessi; Kevin C Johnson; Hege Edvardsen; Nizar Touleimat; Jovana Klajic; Margit Lh Riis; Vilde D Haakensen; Fredrik Wärnberg; Bjørn Naume; Aslaug Helland; Anne-Lise Børresen-Dale; Jörg Tost; Brock C Christensen; Vessela N Kristensen
Journal:  Genome Biol       Date:  2014-08-22       Impact factor: 13.583

3.  Association Analysis of Driver Gene-Related Genetic Variants Identified Novel Lung Cancer Susceptibility Loci with 20,871 Lung Cancer Cases and 15,971 Controls.

Authors:  Yuzhuo Wang; Olga Y Gorlova; Ivan P Gorlov; Meng Zhu; Juncheng Dai; Demetrius Albanes; Stephen Lam; Adonina Tardon; Chu Chen; Gary E Goodman; Stig E Bojesen; Maria Teresa Landi; Mattias Johansson; Angela Risch; Heunz-Erich Wichmann; Heike Bickeboller; David C Christiani; Gad Rennert; Susanne M Arnold; Paul Brennan; John K Field; Sanjay Shete; Loïc Le Marchand; Olle Melander; Hans Brunnstrom; Geoffrey Liu; Rayjean J Hung; Angeline S Andrew; Lambertus A Kiemeney; Shanbeh Zienolddiny; Kjell Grankvist; Mikael Johansson; Neil E Caporaso; Penella J Woll; Philip Lazarus; Matthew B Schabath; Melinda C Aldrich; Victoria L Stevens; Hongxia Ma; Guangfu Jin; Zhibin Hu; Christopher I Amos; Hongbing Shen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-10       Impact factor: 4.254

4.  Generation and characterization of a conditional allele of Interferon Regulatory Factor 6.

Authors:  Arianna L Smith; Youssef A Kousa; Akira Kinoshita; Kate Fodor; Baoli Yang; Brian C Schutte
Journal:  Genesis       Date:  2017-06-22       Impact factor: 2.487

5.  Interferon Regulatory Factor 6 Promotes Keratinocyte Differentiation in Response to Porphyromonas gingivalis.

Authors:  Jennifer Huynh; Glen M Scholz; Jiamin Aw; Eric C Reynolds
Journal:  Infect Immun       Date:  2017-04-21       Impact factor: 3.441

6.  DNA-PKc deficiency drives pre-malignant transformation by reducing DNA repair capacity in concert with reprogramming the epigenome in human bronchial epithelial cells.

Authors:  Ivo Teneng; Maria A Picchi; Shuguang Leng; Christopher P Dagucon; Suresh Ramalingam; Carmen S Tellez; Steven A Belinsky
Journal:  DNA Repair (Amst)       Date:  2019-04-27

7.  Interferon regulatory factor 6 regulates keratinocyte migration.

Authors:  Leah C Biggs; Rachelle L Naridze; Kris A DeMali; Daniel F Lusche; Spencer Kuhl; David R Soll; Brian C Schutte; Martine Dunnwald
Journal:  J Cell Sci       Date:  2014-04-28       Impact factor: 5.285

8.  Dominant mutations in GRHL3 cause Van der Woude Syndrome and disrupt oral periderm development.

Authors:  Myriam Peyrard-Janvid; Elizabeth J Leslie; Youssef A Kousa; Tiffany L Smith; Martine Dunnwald; Måns Magnusson; Brian A Lentz; Per Unneberg; Ingegerd Fransson; Hannele K Koillinen; Jorma Rautio; Marie Pegelow; Agneta Karsten; Lina Basel-Vanagaite; William Gordon; Bogi Andersen; Thomas Svensson; Jeffrey C Murray; Robert A Cornell; Juha Kere; Brian C Schutte
Journal:  Am J Hum Genet       Date:  2013-12-19       Impact factor: 11.025

9.  Expression and mutation analyses implicate ARHGAP29 as the etiologic gene for the cleft lip with or without cleft palate locus identified by genome-wide association on chromosome 1p22.

Authors:  Elizabeth J Leslie; M Adela Mansilla; Leah C Biggs; Kristi Schuette; Steve Bullard; Margaret Cooper; Martine Dunnwald; Andrew C Lidral; Mary L Marazita; Terri H Beaty; Jeffrey C Murray
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2012-09-24

Review 10.  Toward an orofacial gene regulatory network.

Authors:  Youssef A Kousa; Brian C Schutte
Journal:  Dev Dyn       Date:  2015-09-17       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.